Mylan CEO: 'Misconception' about EpiPen profits

September 21, 2016 1:03 PM

1 0

Mylan CEO: 'Misconception' about EpiPen profits

The CEO of the drug maker that sells the EpiPen treatment is expected to defend the company's controversial price increases when she testifies before Congress on Wednesday amid a firestorm over pharmaceutical profits.

Mylan CEO Heather Bresch said there's a "misconception about our profits" from EpiPen, according to a copy of her prepared remarks to be delivered when the House Oversight committee meets at 2 p.m. The emergency allergic reaction injection treatment now costs $608 for a two-pack, up from about $100 ...

Also read: Amgen 3rd-quarter profit tops expectations on cost cutting

Read more

To category page